GoodRx (GDRX) Stock Forecast, Price Target & Predictions
GDRX Stock Forecast
GoodRx stock forecast is as follows: an average price target of $14.57 (represents a 226.68% upside from GDRX’s last price of $4.46) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.
GDRX Price Target
The average price target for GoodRx (GDRX) is $14.57 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $45.00 to $3.00. This represents a potential 226.68% upside from GDRX's last price of $4.46.
GDRX Analyst Ratings
According to 18 Wall Street analysts, GoodRx's rating consensus is 'Buy'. The analyst rating breakdown for GDRX stock is 1 'Strong Buy' (5.56%), 9 'Buy' (50.00%), 8 'Hold' (44.44%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
GoodRx Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 10, 2024 | Craig Hettenbach | Morgan Stanley | $9.50 | $8.55 | 11.11% | 113.00% |
| May 23, 2024 | Mark Mahaney | RBC Capital | $10.00 | $7.20 | 38.89% | 124.22% |
| May 16, 2024 | Stephanie Davis | Barclays | $9.00 | $8.06 | 11.66% | 101.79% |
| May 16, 2024 | Aaron Kessler | Raymond James | $10.00 | $7.27 | 37.55% | 124.22% |
| Apr 10, 2024 | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | $6.92 | 30.06% | 101.79% |
| Apr 10, 2024 | Scott Schoenhaus | KeyBanc | $9.00 | $6.74 | 33.53% | 101.79% |
| Mar 25, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | $7.23 | 38.39% | 124.22% |
| Nov 13, 2023 | Eric Sheridan | Goldman Sachs | $3.00 | $4.73 | -36.58% | -32.74% |
| Dec 01, 2022 | Citigroup | $7.00 | $4.36 | 60.55% | 56.95% | |
| Aug 09, 2022 | Steve Valiquette | Barclays | $13.00 | $7.76 | 67.53% | 191.48% |
| Jun 07, 2022 | Vikram Kesavabhotla | Robert W. Baird | $7.00 | $7.54 | -7.16% | 56.95% |
| May 12, 2022 | Stan Berenshteyn | Wells Fargo | $9.00 | $7.95 | 13.21% | 101.79% |
| Mar 01, 2022 | Doug Anmuth | J.P. Morgan | $20.00 | $16.74 | 19.47% | 348.43% |
| Mar 01, 2022 | Charles Rhyee | Cowen & Co. | $22.00 | $16.74 | 31.42% | 393.27% |
| Mar 01, 2022 | Eric Sheridan | Goldman Sachs | $30.00 | $16.74 | 79.21% | 572.65% |
| Mar 01, 2022 | George Hill | Deutsche Bank | $20.00 | $16.74 | 19.47% | 348.43% |
| Mar 01, 2022 | Justin Post | Bank of America Securities | $28.00 | $16.74 | 67.26% | 527.80% |
| Dec 21, 2021 | Scott Schoenhaus | Stephens | $45.00 | $35.83 | 25.59% | 908.97% |
| May 14, 2021 | Nicholas Jones CFA | Citigroup | $53.00 | $30.97 | 71.13% | 1088.34% |
The latest GoodRx stock forecast, released on Jun 10, 2024 by Craig Hettenbach from Morgan Stanley, set a price target of $9.50, which represents a 11.11% increase from the stock price at the time of the forecast ($8.55), and a 113.00% increase from GDRX last price ($4.46).
GoodRx Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 7 |
| Avg Price Target | - | - | $9.50 |
| Last Closing Price | $4.46 | $4.46 | $4.46 |
| Upside/Downside | -100.00% | -100.00% | 113.00% |
In the current month, the average price target of GoodRx stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to GoodRx's last price of $4.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 16, 2024 | UBS | Buy | Buy | Hold |
| Aug 09, 2024 | Raymond James | Outperform | Strong Buy | Upgrade |
| Jun 10, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 23, 2024 | RBC Capital | Sector Perform | Outperform | Upgrade |
| May 16, 2024 | Barclays | Overweight | Overweight | Hold |
| May 16, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| May 16, 2024 | UBS | Underperform | Underperform | Hold |
| May 16, 2024 | KeyBanc | Overweight | Overweight | Hold |
| May 16, 2024 | Raymond James | Strong Buy | Outperform | Upgrade |
| May 09, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 10, 2024 | KeyBanc | Overweight | Upgrade | |
| Mar 25, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Mar 25, 2024 | UBS | Underperform | Underperform | Hold |
| Mar 25, 2024 | Wells Fargo | Equal-Weight | Overweight | Upgrade |
| Mar 01, 2024 | Cowen & Co. | Outperform | Outperform | Hold |
| Mar 01, 2024 | Barclays | Overweight | Overweight | Hold |
| Nov 13, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Aug 10, 2023 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 10, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Aug 10, 2023 | Credit Suisse | Neutral | Neutral | Hold |
| Aug 10, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 10, 2023 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| Aug 10, 2023 | Morgan Stanley | Equal-Weight | Upgrade | |
| Aug 10, 2023 | RBC Capital | Sector Perform | Underperform | Downgrade |
| Aug 10, 2023 | BMO Capital | Market Perform | Downgrade | |
| Aug 10, 2023 | Craig-Hallum | Neutral | Downgrade | |
| Aug 10, 2023 | Piper Sandler | Overweight | Neutral | Downgrade |
| Jul 31, 2023 | Lake Street | Buy | Initialise | |
| Jul 31, 2023 | Cowen & Co. | Market Perform | Outperform | Upgrade |
| May 11, 2023 | Goldman Sachs | Neutral | Neutral | Hold |
| Dec 01, 2022 | Citigroup | Buy | Initialise | |
| Nov 04, 2022 | Wolfe Research | Peer Perform | Downgrade | |
| Nov 04, 2022 | Raymond James | Market Perform | Strong Buy | Upgrade |
| Nov 04, 2022 | Goldman Sachs | Buy | Neutral | Upgrade |
| Nov 04, 2022 | Piper Sandler | Neutral | Downgrade | |
| Nov 04, 2022 | TD Securities | Buy | Downgrade | |
| Nov 04, 2022 | Oppenheimer | Perform | Downgrade | |
| Nov 04, 2022 | Barclays | Overweight | Equal-Weight | Downgrade |
| Aug 09, 2022 | Barclays | Overweight | Overweight | Hold |
| Jun 29, 2022 | Cowen & Co. | Market Perform | Market Perform | Hold |
| May 12, 2022 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| May 11, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 10, 2022 | Raymond James | Market Perform | Downgrade | |
| May 10, 2022 | RBC Capital | Outperform | Sector Perform | Downgrade |
| Mar 03, 2022 | Deutsche Bank | Hold | Hold | Hold |
| Nov 15, 2021 | SVB Leerink | Outperform | Outperform | Hold |
| May 16, 2021 | RBC Capital | Outperform | Outperform | Hold |
| Nov 23, 2020 | Goldman Sachs | Neutral | Neutral | Hold |
GoodRx's last stock rating was published by Cowen & Co. on Oct 01, 2024. The company gave GDRX a "Buy" rating, the same as its previous rate.
GoodRx Financial Forecast
GoodRx Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $196.64M | $179.96M | $189.68M | $183.99M | $184.11M | $187.32M | $191.80M | $203.33M | $213.26M | $195.10M | $176.63M | $160.43M | $153.54M | $140.45M |
| Avg Forecast | $224.02M | $220.26M | $222.25M | $216.63M | $209.62M | $206.25M | $207.74M | $202.78M | $199.76M | $195.66M | $200.47M | $196.11M | $194.30M | $188.52M | $186.84M | $182.09M | $178.50M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
| High Forecast | $229.28M | $225.43M | $227.47M | $221.72M | $214.55M | $211.10M | $212.62M | $212.14M | $200.15M | $196.53M | $200.47M | $196.11M | $194.74M | $188.53M | $191.23M | $186.37M | $182.69M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
| Low Forecast | $219.45M | $215.76M | $217.72M | $212.22M | $205.35M | $202.05M | $203.51M | $196.28M | $199.42M | $194.78M | $200.47M | $196.11M | $193.12M | $188.51M | $183.03M | $178.38M | $174.86M | $185.04M | $184.71M | $200.45M | $217.46M | $194.78M | $174.58M | $160.62M | $147.82M | $135.07M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.95% | 1.02% | 1.01% | 1.03% | 1.01% | 1.04% | 1.01% | 0.98% | 1.00% | 1.01% | 1.00% | 1.04% | 1.04% |
GoodRx's average Quarter revenue forecast for Mar 24 based on 4 analysts is $196.11M, with a low forecast of $196.11M, and a high forecast of $196.11M. GDRX's average Quarter revenue forecast represents a -0.27% decrease compared to the company's last Quarter revenue of $196.64M (Dec 23).
GoodRx EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.68M | $-12.09M | $42.22M | $31.67M | $22.71M | $1.16M | $10.13M | $31.19M | $22.42M | $17.17M | $8.03M | $379.00K | $-295.01M | $-56.50M |
| Avg Forecast | $9.83M | $9.66M | $9.75M | $9.50M | $9.20M | $9.05M | $9.11M | $8.90M | $8.76M | $8.58M | $8.80M | $37.43M | $8.52M | $8.27M | $8.20M | $29.59M | $31.20M | $10.69M | $10.67M | $23.39M | $12.57M | $11.26M | $10.09M | $379.00K | $8.54M | $-49.44M |
| High Forecast | $10.06M | $9.89M | $9.98M | $9.73M | $9.41M | $9.26M | $9.33M | $9.31M | $8.78M | $8.62M | $8.80M | $44.91M | $8.54M | $8.27M | $8.39M | $35.51M | $37.44M | $10.69M | $10.67M | $28.07M | $12.57M | $11.26M | $10.09M | $454.80K | $8.54M | $-39.55M |
| Low Forecast | $9.63M | $9.47M | $9.55M | $9.31M | $9.01M | $8.86M | $8.93M | $8.61M | $8.75M | $8.55M | $8.80M | $29.94M | $8.47M | $8.27M | $8.03M | $23.67M | $24.96M | $10.69M | $10.67M | $18.71M | $12.57M | $11.26M | $10.09M | $303.20K | $8.54M | $-59.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.20% | -1.46% | 5.15% | 1.07% | 0.73% | 0.11% | 0.95% | 1.33% | 1.78% | 1.53% | 0.80% | 1.00% | -34.53% | 1.14% |
4 analysts predict GDRX's average Quarter EBITDA for Mar 24 to be $37.43M, with a high of $44.91M and a low of $29.94M. This is 2122.59% upper than GoodRx's previous annual EBITDA (Dec 23) of $1.68M.
GoodRx Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-25.87M | $-38.49M | $58.79M | $-3.29M | $-1.97M | $-41.73M | $-1.42M | $12.29M | $-39.91M | $-18.07M | $31.06M | $1.67M | $-298.27M | $-50.03M |
| Avg Forecast | $48.19M | $45.81M | $47.89M | $44.51M | $44.07M | $40.52M | $39.69M | $37.40M | $37.13M | $33.78M | $33.78M | $14.75M | $26.22M | $22.57M | $23.51M | $11.66M | $-55.54M | $16.33M | $15.17M | $9.22M | $38.04M | $33.53M | $30.31M | $1.67M | $25.10M | $-43.78M |
| High Forecast | $49.66M | $47.21M | $49.36M | $45.87M | $45.41M | $41.76M | $40.91M | $41.55M | $41.25M | $33.79M | $34.55M | $17.70M | $32.78M | $23.26M | $24.23M | $14.00M | $-44.43M | $16.33M | $15.17M | $11.06M | $38.04M | $33.53M | $30.31M | $2.00M | $25.10M | $-35.02M |
| Low Forecast | $46.91M | $44.59M | $46.62M | $43.33M | $42.90M | $39.45M | $38.64M | $36.41M | $33.00M | $33.77M | $33.01M | $11.80M | $19.67M | $21.98M | $22.89M | $9.33M | $-66.65M | $16.33M | $15.17M | $7.38M | $38.04M | $33.53M | $30.31M | $1.33M | $25.10M | $-52.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.99% | -1.71% | 2.50% | -0.28% | 0.04% | -2.56% | -0.09% | 1.33% | -1.05% | -0.54% | 1.02% | 1.00% | -11.88% | 1.14% |
GoodRx's average Quarter net income forecast for Sep 23 is $22.57M, with a range of $21.98M to $23.26M. GDRX's average Quarter net income forecast represents a -61.60% decrease compared to the company's last Quarter net income of $58.79M (Jun 23).
GoodRx SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $124.12M | $126.93M | $107.65M | $108.14M | $112.71M | $135.76M | $129.08M | $124.87M | $141.87M | $131.60M | $127.96M | $123.48M | $415.69M | $173.59M |
| Avg Forecast | $169.21M | $166.37M | $167.88M | $163.63M | $158.34M | $155.79M | $156.92M | $153.17M | $150.89M | $147.79M | $151.42M | $149.87M | $146.77M | $142.40M | $141.13M | $118.47M | $134.83M | $136.24M | $136.00M | $93.65M | $160.11M | $143.42M | $128.54M | $123.48M | $108.84M | $99.45M |
| High Forecast | $173.19M | $170.28M | $171.82M | $167.48M | $162.06M | $159.45M | $160.61M | $160.24M | $151.19M | $148.45M | $151.42M | $179.84M | $147.10M | $142.41M | $144.45M | $142.17M | $137.99M | $136.24M | $136.00M | $112.39M | $160.11M | $143.42M | $128.54M | $148.18M | $108.84M | $99.45M |
| Low Forecast | $165.76M | $162.98M | $164.46M | $160.30M | $155.11M | $152.62M | $153.72M | $148.26M | $150.63M | $147.13M | $151.42M | $119.89M | $145.87M | $142.39M | $138.25M | $94.78M | $132.08M | $136.24M | $136.00M | $74.92M | $160.11M | $143.42M | $128.54M | $98.78M | $108.84M | $99.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.85% | 0.89% | 0.76% | 0.91% | 0.84% | 1.00% | 0.95% | 1.33% | 0.89% | 0.92% | 1.00% | 1.00% | 3.82% | 1.75% |
GoodRx's average Quarter SG&A projection for Mar 24 is $149.87M, based on 4 Wall Street analysts, with a range of $119.89M to $179.84M. The forecast indicates a 20.74% rise compared to GDRX last annual SG&A of $124.12M (Dec 23).
GoodRx EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.06 | $-0.09 | $0.14 | $-0.01 | $-0.00 | $-0.10 | $-0.00 | $0.03 | $-0.10 | $-0.04 | $0.08 | - | $-0.74 | $-0.21 |
| Avg Forecast | $0.12 | $0.12 | $0.12 | $0.11 | $0.11 | $0.10 | $0.10 | $0.10 | $0.10 | $0.09 | $0.09 | $0.08 | $0.07 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
| High Forecast | $0.13 | $0.12 | $0.13 | $0.12 | $0.12 | $0.11 | $0.11 | $0.11 | $0.11 | $0.09 | $0.09 | $0.08 | $0.08 | $0.06 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
| Low Forecast | $0.12 | $0.11 | $0.12 | $0.11 | $0.11 | $0.10 | $0.10 | $0.09 | $0.08 | $0.09 | $0.08 | $0.07 | $0.05 | $0.06 | $0.06 | $0.05 | $0.04 | $0.04 | $0.04 | $0.08 | $0.10 | $0.09 | $0.08 | $0.07 | $0.07 | $0.08 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.95% | -1.60% | 2.31% | -0.14% | -0.10% | -2.36% | -0.09% | 0.37% | -0.98% | -0.46% | 1.02% | 0.06% | -11.34% | -2.77% |
According to 4 Wall Street analysts, GoodRx's projected average Quarter EPS for Sep 23 is $0.06, with a low estimate of $0.06 and a high estimate of $0.06. This represents a -58.50% decrease compared to GDRX previous annual EPS of $0.14 (Jun 23).
GoodRx Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AMWL | American Well | $8.45 | $148.13 | 1653.02% | Hold |
| GDRX | GoodRx | $4.46 | $14.57 | 226.68% | Buy |
| EVH | Evolent Health | $10.87 | $33.00 | 203.59% | Buy |
| ACCD | Accolade | $3.40 | $8.08 | 137.65% | Buy |
| TXG | 10x Genomics | $14.72 | $31.75 | 115.69% | Hold |
| SLP | Simulations Plus | $30.04 | $47.00 | 56.46% | Buy |
| PGNY | Progyny | $14.74 | $22.67 | 53.80% | Hold |
| DH | Definitive Healthcare | $4.46 | $6.08 | 36.32% | Hold |
| SDGR | Schrödinger | $21.36 | $28.50 | 33.43% | Buy |
| CERT | Certara | $11.40 | $15.00 | 31.58% | Buy |
| HCAT | Health Catalyst | $7.65 | $9.67 | 26.41% | Buy |
| GEHC | GE HealthCare | $79.25 | $92.00 | 16.09% | Buy |
| PRVA | Privia Health Group | $20.79 | $23.00 | 10.63% | Buy |
| TDOC | Teladoc Health | $10.07 | $11.00 | 9.24% | Buy |
| VEEV | Veeva Systems | $226.41 | $235.50 | 4.01% | Buy |
| DOCS | Doximity | $52.70 | $53.38 | 1.29% | Buy |
| HSTM | HealthStream | $31.97 | $29.00 | -9.29% | Buy |
| TALK | Talkspace | $3.26 | $2.50 | -23.31% | Hold |